This company has been acquired
Exscientia (EXAI) Stock Overview
An artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
EXAI Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Exscientia plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.84 |
| 52 Week High | US$7.91 |
| 52 Week Low | US$3.80 |
| Beta | 0.84 |
| 1 Month Change | -0.62% |
| 3 Month Change | -19.33% |
| 1 Year Change | -21.94% |
| 3 Year Change | -75.60% |
| 5 Year Change | n/a |
| Change since IPO | -82.14% |
Recent News & Updates
Recent updates
Recursion's Acquisition Of Exscientia Makes Sense On Some Levels, Not Others
Aug 08Here's Why We're Watching Exscientia's (NASDAQ:EXAI) Cash Burn Situation
Jul 17
Exscientia: Too Much Pessimism
Jun 10Exscientia: Drug Discovery Platform Attracting Partners And Cash
May 22Exscientia: A Strategic Hold In The AI-Driven Drug Discovery Sector (Rating Downgrade)
Feb 26Is Exscientia (NASDAQ:EXAI) In A Good Position To Invest In Growth?
Jan 11Earnings Update: Exscientia plc (NASDAQ:EXAI) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts
Nov 12New Forecasts: Here's What Analysts Think The Future Holds For Exscientia plc (NASDAQ:EXAI)
Aug 31We're Keeping An Eye On Exscientia's (NASDAQ:EXAI) Cash Burn Rate
Aug 25Broker Revenue Forecasts For Exscientia plc (NASDAQ:EXAI) Are Surging Higher
Jul 21Exscientia (NASDAQ:EXAI) Is In A Good Position To Deliver On Growth Plans
Apr 22We're Not Very Worried About Exscientia's (NASDAQ:EXAI) Cash Burn Rate
Dec 30The Exscientia plc (NASDAQ:EXAI) Analysts Have Been Trimming Their Sales Forecasts
Aug 31Exscientia: Using AI To Power Drug Development
Aug 15Companies Like Exscientia (NASDAQ:EXAI) Can Afford To Invest In Growth
May 29Shareholder Returns
| EXAI | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 3.2% | -0.2% | 0.2% |
| 1Y | -21.9% | 28.4% | 18.7% |
Return vs Industry: EXAI underperformed the US Biotechs industry which returned 15.2% over the past year.
Return vs Market: EXAI underperformed the US Market which returned 31.1% over the past year.
Price Volatility
| EXAI volatility | |
|---|---|
| EXAI Average Weekly Movement | 8.5% |
| Biotechs Industry Average Movement | 11.3% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: EXAI has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: EXAI's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 483 | Dave Hallett | www.exscientia.ai |
Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company’s lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy. It is also involved in the development of EXS4318, a PKC-theta inhibitor, under Phase 1 clinical trial for inflammation and immunology indications; EXS74539, a LSD1 inhibitor, under preclinical studies for SCLC, AML, and potential additional indications; EXS73565, a MALT1 inhibitor, under preclinical studies for multiple hematology indications; and DSP-0038, currently in Phase 1 studies.
Exscientia plc Fundamentals Summary
| EXAI fundamental statistics | |
|---|---|
| Market cap | US$633.50m |
| Earnings (TTM) | -US$188.33m |
| Revenue (TTM) | US$21.36m |
Is EXAI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EXAI income statement (TTM) | |
|---|---|
| Revenue | UK£17.07m |
| Cost of Revenue | UK£28.63m |
| Gross Profit | -UK£11.56m |
| Other Expenses | UK£138.95m |
| Earnings | -UK£150.51m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.15 |
| Gross Margin | -67.74% |
| Net Profit Margin | -881.79% |
| Debt/Equity Ratio | 0.1% |
How did EXAI perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/11/22 03:06 |
| End of Day Share Price | 2024/11/19 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Exscientia plc is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Alec Stranahan | BofA Global Research |
| Chris Shibutani | Goldman Sachs |
| Brendan Smith | TD Cowen |